Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Gynecologic disease is commonly encountered in women infected with the human immunodeficiency virus (HIV). The clinical course of cervical intraepithelial neoplasia, invasive cervical cancer, pelvic inflammatory disease, syphilis, and vaginal candidiasis may be altered by HIV infection and may be refractory to standard treatment, especially with increasing degrees of immune suppression. Careful screening for gynecologic disease and vigilant surveillance for treatment failure are important in the care of women infected with HIV.
 ...
PMID:Gynecologic disease in women infected with human immunodeficiency virus type 1. 760 Jan 2

In the US, women comprise the population group with the most rapidly increasing rate of human immunodeficiency virus (HIV) infection, yet these women--predominantly poor and Black or Hispanic--must face the added trauma of discrimination in the health care system. Even the clinical case definition of acquired immunodeficiency syndrome (AIDS) fails to include recurrent pelvic inflammatory disease, recurrent vulvovaginal candidiasis, and cervical carcinoma in situ, thereby excluding thousands of women from AIDS-related entitlements. Essential for HIV-infected women is empowerment to facilitate sound decision making about choice of partners, barrier contraception, pregnancy, abortion, and breast feeding. The vast majority of women with sex partners in high-risk groups do not use condoms, in part because of fear of loss of the relationship or withdrawal of financial support. HIV-positive women are especially in need of condom use to prevent further transmission and unwanted pregnancy. Pregnancy in HIV-positive women is associated with a 30% chance that the infant will acquire the infection and alarming increases in the ranks of the 20,000 US children already orphaned by AIDS. Nonetheless, the right of HIV-infected women to bear children should be protected, and these women should be given the option of artificial insemination of washed semen and Cesarean section delivery to reduce the risk of transmission to partner and child. Finally, because substance abusing women are not always able to make appropriate decisions about their sexual practices, drug treatment on demand and comprehensive outreach programs for HIV-infected women at shelters, the streets, and shooting galleries must be implemented.
 ...
PMID:Dissemination of HIV: how serious is it for women, medically and psychologically? 771 Jan 97

Genital ulcers are implicated as a risk factor enhancing susceptibility to human immunodeficiency virus type 1 (HIV-1) infection. A prospective study to determine the incidence of and risk factors associated with acquisition of HIV-1 in women with genital ulcers was done. HIV-1-seronegative women with genital ulcers attending a clinic for sexually transmitted diseases in Nairobi were followed to HIV-1 seroconversion over a 6-month period. Of 81 women, 10 seroconverted to HIV-1. The crude 6-month incidence of HIV-1 infection was 12%. Risk factors associated with seroconversion included cervical ectopy (rate ratio [RR], 4.9; 95% confidence interval [CI], 1.5-15.6) and pelvic inflammatory disease (RR, 6.3; 95% CI, 1.9-20.4). Thus, cervical ectopy and pelvic inflammatory disease may increase susceptibility to HIV-1 in women with genital ulcers.
 ...
PMID:Human immunodeficiency virus type 1 seroconversion in women with genital ulcers. 765 94

As the human immunodeficiency virus (HIV) epidemic affects more women, clinicians are increasingly observing pelvic inflammatory disease (PID) in HIV-infected women. The extent to which PID is a factor in the recognition of HIV or HIV is a factor in the recognition of PID is unknown. Even less is known about how HIV infection influences the development, clinical course, and microbiology of PID. The paucity of existing data largely results from difficulties in designing studies that are free of bias. Several biases may distort studies of the effect of HIV on the recognition, incidence, clinical presentation and course, and microbiology of PID. Selection bias, diagnostic bias, and confounding bias are the most likely causes of invalid conclusions in studies of the influence of HIV infection on these aspects of PID, for three major reasons: Factors that determine patients' health care seeking behavior may be related to HIV status; the diagnosis of PID tends to be imprecise; and extraneous factors that cause or prevent PID may be distributed differently in HIV-infected and HIV-uninfected women. Appropriate study design and analytic techniques can eliminate, reduce, or estimate the magnitude and direction of these biases, thereby yielding more valid conclusions. To interpret properly existing and future studies of the influence of HIV infection on PID, clinicians must consider several biases that may distort results.
 ...
PMID:Potential for bias in studies of the influence of human immunodeficiency virus infection on the recognition, incidence, clinical course, and microbiology of pelvic inflammatory disease. 805 50

These guidelines for the treatment of patients with sexually transmitted diseases (STDs) were developed by staff members of CDC after consultation with a group of invited experts who met in Atlanta on January 19-21, 1993. Included are new recommendations for single-dose oral therapy for gonococcal infections, chlamydial infections, and chancroid; new regimens for the treatment of bacterial vaginosis (BV) and outpatient management of pelvic inflammatory disease (PID); a new patient-applied medication for treatment of genital warts; and a revised approach to the management of victims of sexual assault. This report includes new sections on subclinical human papillomavirus (HPV) infections and cervical cancer screening for women who attend STD clinics or who have a history of STDs. These recommendations also include expanded sections on the management of patients with asymptomatic human immunodeficiency virus (HIV) infection; vulvovaginal candidiasis (VVC); STDs among patients coinfected with HIV; and STDs among infants, children, and pregnant women.
 ...
PMID:1993 sexually transmitted diseases treatment guidelines. Centers for Disease Control and Prevention. 814 6

Noncontraceptive actions of oral contraceptives (OCs) include hormonal effects on bone mass, sexually transmitted disease, pelvic inflammatory disease, the cardiovascular system, menstrual function, and future fertility. Information about the effects of OCs on bone mass is limited and contradictory. Two recent studies failed to show a positive effect of OC use on bone mass or density compared with the three cross-sectional studies and one longitudinal study that showed favorable effects. A recently completed study of 156 healthy females indicated a significant correlation between OC use and the rate of change in total body bone-mineral content. One study involving depot medroxyprogesterone acetate suggests bone density decreases with long-term use of the drug. The use of OCs does not reduce the risk of gonococcal or chlamydial infection of the lower tract and in fact may enhance spread of lower tract infection. However, OCs may exert a protective effect against some types of pelvic inflammatory disease. Regarding transmission of human immunodeficiency virus, the results of recent studies are conflicting. Research related to newer OC formulations containing 35 micrograms or less of ethinyl estradiol suggests that the risk of a negative cardiovascular effect is substantially reduced. All forms of hormonal contraception alter menstrual function to some degree, but most patterns improve with duration of use. No evidence exists that hormonal contraception permanently affects fertility, although fertility restoration may be delayed with some agents.
 ...
PMID:Noncontraceptive effects of hormonal contraceptives: bone mass, sexually transmitted disease and pelvic inflammatory disease, cardiovascular disease, menstrual function, and future fertility. 817 8

Spermicides kill a wide range of bacteria and viruses causing sexually transmitted diseases (STDs), including the human immunodeficiency virus (HIV) in vitro, and protect in vivo from infection by gonorrhoea, chlamydia, and pelvic inflammatory disease (PID). In the UK and the US, the most commonly used compound in spermicidal agents is the neutral surfactant nonoxynol-9. Although spermicides reduce the incidence of reinfection by some STDs, an in vivo virucidal action is not supported by convincing data. Among barrier methods, latex condoms provide an impervious barrier in vitro to most STD pathogens, including HIV. Natural condoms made of sheep intestinal membrane can allow passage of hepatitis B viral particles but not HIV in vitro. Several studies have shown protection against cervical gonorrhoea and PID among diaphragm users; however, diaphragm use has been associated with an increased rate of urinary infection and also bacterial vaginosis. It is conceivable that women using oral contraceptives (OCs) do not develop as much tubal damage as women not using OCs because of a modified immunological reaction. A study carried out in Europe showed a statistically significant protective effect against PID of the levonorgestrel-containing IUD as compared with the copper-containing Nova-T. A case/control study of 1028 women in Chicago in 1970 noted admission for PID during the following 7 years of only 1 woman who had been sterilized compared to 9 controls. A case/control study examining risk factors for cervical intraepithelial neoplasia (CIN) in 103 women with biopsy-confirmed CIN II or III did not find an increased risk with either OC or IUD use after adjusting for other known risk factors. After adjustment for age and education, the odds ratio for diaphragm use was .3 and the odds ratio for condom use was .5. Thus, hormonal contraception and tubal ligation give protection to the upper genital tract but not to the cervix.
 ...
PMID:Contraception and the prevention of sexually transmitted diseases. 832 7

To better understand the clinical manifestations of human immunodeficiency virus (HIV) infection in women in Louisiana, we conducted a retrospective review of the records of HIV-infected women who presented to the largest HIV outpatient clinic in Louisiana as well as to a tertiary care university hospital in New Orleans between January 1987 and December 1991. A total of 224 women were evaluated. Gynecologic examinations revealed that 17.5% had cervical intraepithelial neoplasia and that 35% had evidence of candidal vulvovaginitis or colonization. The following conditions were diagnosed among indicated percentages of patients: syphilis, 22.2%; Neisseria gonorrhoeae infection, 7.2%; Chlamydia trachomatis infection, 12.3%; pelvic inflammatory disease, 5.3%; trichomonal vulvovaginitis, 26.9%; genital ulcers due to herpes simplex virus, 16.5%; and clinically evident genital human papillomavirus infections, 16.5%. Both trichomonal vulvovaginitis and syphilis were more common among intravenous drug users. A total of 82 opportunistic processes were observed in 55 women. Pneumocystis carinii pneumonia was the most frequent complication of AIDS, followed by candidal esophagitis and wasting syndrome. Over 85% of women had received a diagnosis of AIDS before death. Gynecologic diseases occurred often in this population; the frequency of AIDS-defining events was similar to that reported previously in the literature.
 ...
PMID:Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. 839 61

Among 302 female sex workers in Nairobi, Kenya, who were followed for 17.6 +/- 11.1 months, 146 had one or more infections with Chlamydia trachomatis; 102 had uncomplicated cervical infection only, 23 had C. trachomatis pelvic inflammatory disease (PID), and 21 had combined C. trachomatis and Neisseria gonorrhoeae PID. As determined by multivariate logistic regression analysis, risk factors for C. trachomatis PID included repeated C. trachomatis infection (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.3-2.4; P = .0004), antibody to C. trachomatis heat-shock protein 60 (OR, 3.9; CI, 1.04-14.5; P = .04), oral contraceptive use (OR, 0.28; 95% CI, 0.08-0.99; P = .048), and number of episodes of nongonococcal nonchlamydial PID (OR, 1.7; 95% CI, 1.1-2.7; P = .02). Among human immunodeficiency virus (HIV)-seropositive women, a CD4 lymphocyte count of <400/mm3 was an additional independent risk factor for C. trachomatis PID (OR, 21.7; 95% CI, 1.2-383; P = .036); among HLA-typed women, HLA-A31 was independently associated with C. trachomatis PID (OR, 5.6; 95% CI, 1.1-29.4; P = .043). The results suggest an immune-mediated pathogenesis for C. trachomatis PID.
 ...
PMID:Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. 864 17

The proportion of women infected with the human immunodeficiency virus (HIV) continues to increase. Over one-half of women acquire the virus through heterosexual contact. The diagnoses that define the acquired immunodeficiency syndrome and the use of antiretroviral therapy are similar in men and women, except in pregnancy. However, management decisions differ significantly regarding contraceptive and gynecologic care. Besides abstinence, use of the latex condom continues to be the most effective way of preventing transmission of HIV. The management of human papillomavirus-associated disease, pelvic inflammatory disease and vaginal candidiasis is especially challenging in women with HIV infection. A positive status for the virus does not appear to affect pregnancy outcome. Each year, up to 2,000 infants are born infected with HIV. Transmission can occur by transplacental or intrapartum spread or through breast milk. Since 1994, prophylaxis with zidovudine has been shown to be an effective method of limiting transmission to infants. It is important to offer all pregnant women a test for HIV, with counseling provided both before and after the test, even if testing does not become mandatory under the law.
 ...
PMID:HIV infection in women: an escalating health concern. 885 78


<< Previous 1 2 3 4 5 6 7 8 9 Next >>